Interferon Alpha Treatment of Patients with Impaired Interferon Gamma Signaling

[1]  J. Cañete,et al.  Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report. , 2012, Seminars in arthritis and rheumatism.

[2]  J. Casanova,et al.  Mycobacterial Disease and Impaired IFN-γ Immunity in Humans with Inherited ISG15 Deficiency , 2012, Science.

[3]  C. Khor,et al.  Genome-Wide Expression Profiling Identifies Type 1 Interferon Response Pathways in Active Tuberculosis , 2012, PloS one.

[4]  J. Hamilton,et al.  Defining GM-CSF– and Macrophage-CSF–Dependent Macrophage Responses by In Vitro Models , 2012, The Journal of Immunology.

[5]  J. Casanova,et al.  Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes , 2012, Current Opinion in Immunology.

[6]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[7]  J. Casanova,et al.  Inborn errors of human JAKs and STATs. , 2012, Immunity.

[8]  U. Grohmann,et al.  Indoleamine 2,3‐dioxygenase: From catalyst to signaling function , 2012, European journal of immunology.

[9]  C. Kauffman,et al.  Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy , 2009, Drugs.

[10]  G. Keating.  Peginterferon-α-2a (40 kD) , 2012, Drugs.

[11]  A. Sher,et al.  Innate and adaptive interferons suppress IL-1α and IL-1β production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. , 2011, Immunity.

[12]  T. Myers,et al.  This information is current as Production in Human Macrophages β Type I IFN Signaling To Regulate IL-1 Triggers Host Mycobacterium tuberculosis , 2011 .

[13]  E. Besada.  Rapid growing mycobacteria and TNF-α blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review. , 2011, Clinical and experimental rheumatology.

[14]  N. Savage,et al.  IFN-α cannot substitute lack of IFN-γ responsiveness in cells of an IFN-γR1 deficient patient. , 2011, Clinical immunology.

[15]  J. Casanova,et al.  Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. , 2011, Human molecular genetics.

[16]  G. Trinchieri,et al.  Type I interferon: friend or foe? , 2010, The Journal of experimental medicine.

[17]  Virginia Pascual,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2010, Nature.

[18]  S. Schreiber,et al.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement , 2010, European Respiratory Journal.

[19]  A. Sher,et al.  Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. , 2010, The Journal of clinical investigation.

[20]  Lionel B Ivashkiv,et al.  Type I interferon: a new player in TNF signaling. , 2010, Current directions in autoimmunity.

[21]  William M. Lee,et al.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. , 2009, The New England journal of medicine.

[22]  Lionel B Ivashkiv,et al.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. , 2009, Immunity.

[23]  A. Aghemo,et al.  Pegylated IFN-α2a and ribavirin in the treatment of hepatitis C , 2009, Expert review of anti-infective therapy.

[24]  K. Winthrop,et al.  Nontuberculous Mycobacteria Infections and Anti–Tumor Necrosis Factor-α Therapy , 2009, Emerging infectious diseases.

[25]  C. Kauffman,et al.  Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. , 2009, Drugs.

[26]  G. Keating.  Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. , 2009, Drugs.

[27]  C. MacKenzie,et al.  Antimicrobial and immunoregulatory effects mediated by human lung cells: role of IFN-gamma-induced tryptophan degradation. , 2008, FEMS immunology and medical microbiology.

[28]  Smita Y. Patel,et al.  Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN-γ receptor 2 deficiency , 2007, Virchows Archiv.

[29]  S. Smirnov,et al.  Adjunctive treatment of disseminated Mycobacterium avium complex infection with interferon alpha-2b in a patient with complete interferon-gamma receptor R1 deficiency , 2007, European Journal of Pediatrics.

[30]  Alberto Mantovani,et al.  Transcriptional Profiling of the Human Monocyte-to-Macrophage Differentiation and Polarization: New Molecules and Patterns of Gene Expression1 , 2006, The Journal of Immunology.

[31]  C. Harding,et al.  Interferon‐αβ mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette–Guérin infection , 2006 .

[32]  C. Harding,et al.  Interferon-alphabeta mediates partial control of early pulmonary Mycobacterium bovis bacillus Calmette-Guérin infection. , 2006, Immunology.

[33]  M. Newport,et al.  Clinical features of dominant and recessive interferon γ receptor 1 deficiencies , 2004, The Lancet.

[34]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[35]  D. Underhill.  Faculty Opinions recommendation of Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. , 2004 .

[36]  S. Holland,et al.  Long-Term Interferon-γ Therapy for Patients with Chronic Granulomatous Disease , 2004 .

[37]  M. Newport,et al.  Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. , 2004, Lancet.

[38]  S. Holland,et al.  Long-term interferon-gamma therapy for patients with chronic granulomatous disease. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  E. Coccia,et al.  IFN-αβ Released by Mycobacterium tuberculosis-Infected Human Dendritic Cells Induces the Expression of CXCL10: Selective Recruitment of NK and Activated T Cells 1 , 2003, The Journal of Immunology.

[40]  E. Coccia,et al.  IFN-alpha beta released by Mycobacterium tuberculosis-infected human dendritic cells induces the expression of CXCL10: selective recruitment of NK and activated T cells. , 2003, Journal of immunology.

[41]  N. Boéchat,et al.  Alpha/Beta Interferon Impairs the Ability of Human Macrophages To Control Growth of Mycobacterium bovis BCG , 2002, Infection and Immunity.

[42]  G. Kaplan,et al.  Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Holland.  Immunotherapy of mycobacterial infections. , 2001, Seminars in respiratory infections.

[44]  U. Hanaoka,et al.  Antenatal ultrasonographic features of fetal giant hemangiolymphangioma , 2001, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[45]  S. Dorman,et al.  Abnormal Regulation of Interferon-γ, Interleukin-12, and Tumor Necrosis Factor-α in Human Interferon-γ Receptor 1 Deficiency , 1998 .

[46]  S. Dorman,et al.  Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobacterial infection. , 1998, The Journal of clinical investigation.

[47]  S. Dorman,et al.  Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. , 1998, The Journal of infectious diseases.

[48]  M. Fricová,et al.  [Interferon alpha in the treatment of chronic myeloid leukemia]. , 1996, Vnitrni lekarstvi.

[49]  R. Rodriguiz,et al.  Long-term treatment of osteopetrosis with recombinant human interferon gamma. , 1995, The New England journal of medicine.

[50]  M. Denis.  Recombinant murine beta interferon enhances resistance of mice to systemic Mycobacterium avium infection , 1991, Infection and immunity.